COPD Department of Internal Medicine Yonsei University College of Medicine Jae Ho Chung.

Slides:



Advertisements
Similar presentations
Chronic obstructive bronchitis and emphysema
Advertisements

Definition of COPD COPD is a preventable and treatable disease with some significant extrapulmonary effects that may contribute to the severity in individual.
GOLD MANAGEMENT PLAN FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
New COPD GOLD Classification
BY DR.Khaled Helmy Chest Specialist Al Mahmora Chest Hospital Ministry of Health - Egypt COPD SCOPE ON.
Academy Board Prep PCCM
Pre-Hospital Treatment Using the Respironics Whisperflow
Chronic obstructive pulmonary diseases (COPD)
Disorders of the respiratory system 2
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Disorders of the respiratory system 2. Bronchitis is an obstructive respiratory disease that may occur in both acute and chronic forms. Acute bronchitis:
Copyright © 2010 Delmar, Cengage Learning. ALL RIGHTS RESERVED. Chapter 13 Resistance-Training Strategies for Individuals with Chronic Obstructive Pulmonary.
LUNG FUNCTION IN HEALTH AND DISEASE: SPIROMETRY Sultan Ayoub Meo MBBS, PGC Med Ed, PG Dip Med Ed, M.Phil, Ph.D Professor, Department of Physiology, College.
Dr. Danny Galdermans Dept Respiratory Medicine ZNA Middelheim Antwerp
Applied Epidemiology Epidemiology of Chronic Obstructive Pulmonary Disease (COPD) By Chris Callan 23 April 2008.
By: E. Salehifar Clinical Pharmacist
COPD (Chronic Obstructive Pulmonary Disease)
Dr. Maha Al-Sedik. Why do we study respiratory emergency?  Respiratory Calls are some of the most Common calls you will see.  Respiratory care is.
ASTHMA AND COPD By Jess Laidlaw. Overview 1)Asthma 2)COPD 3)Comparison.
Chronic Obstructive Pulmonary Disease (COPD) Abtahi H, MD Packnejad, MD.
Disorders of the respiratory system. Respiratory structures such as the airways, alveoli and pleural membranes may all be affected by various disease.
(C.O.P.D) Ch.Bronchitis Emphysema (C.O.P.D) Ch.Bronchitis Emphysema AISHA M SIDDIQUI.
Management of Patients With Chronic Pulmonary Disease.
Definition of COPD COPD is a preventable and treatable disease with some significant extrapulmonary effects that may contribute to the severity in individual.
Chronic Obstructive Pulmonary Diseases (COPD)
COPD Review. Progressive Syndrome Expiratory airflow obstruction Chronic airway and lung parenchyma inflammation.
Pathology of chronic obstructive airway diseases
Obstructive and restrictive respiratory diseases
World COPD Day 2005 Slide Kit
Chronic Obstructive Pulmonary Disease. Why COPD is Important ? COPD is the only chronic disease that is showing progressive upward trend in both mortality.
PULMONARY PATHOLOGY Prof Frank Carey. General Approach r Understanding mechanisms of disease r Emphasizing the role of the pathologist in diagnosis.
Chronic Obstructive Pulmonary Disease Dr. Pawan K. Mangla, M.D., INTENSIVIST & PULMONOLOGIST ISIC & PSRI HOSPITAL Brought to you by IJCP Group of Publications.
Chronic Obstructive Pulmonary Disease
Habib GHEDIRA, MD, Prof. Medical Faculty of Tunis
1 Respiratory Disorders II. 2 Lecture Outline 1- Spirometry: Volume/Time & Flow/Volume Curves 2- Use of Spirometry in Obstructive & Restrictive Lung Diseases.
2008 Canadian COPD Guidelines Definition of COPD: “Chronic obstructive pulmonary disease (COPD) is a respiratory disorder largely caused by smoking which.
Pulmonary Pathology Obstructive Airways Disease. Respiratory disease Pulmonary diseases (especially infective) together with gastrointestinal infection.
Copyright © 2008 Wolters Kluwer Health | Lippincott Williams & Wilkins Emphysema Abnormal distention of air spaces beyond the terminal bronchioles with.
يکشنبه، 2015/10/11يکشنبه، 2015/10/11يکشنبه، 2015/10/11يکشنبه، 2015/10/11يکشنبه، 2015/10/11يکشنبه، 2015/10/11 بسم الله الرحمن الرحیم با سلام.
Chronic obstructive pulmonary disease. Chronic obstructive pulmonary disease (COPD)  Permanent reduction in airflow in the lung  Caused by smoking,
Chronic Obstructive Lung Diseases (COPD) Lecture
Chronic Obstructive Pulmonary Disease
OBSTRUCTIVE AIRWAY DISEASE
Chronic Obstructive Pulmonary Disease Austin Paul K.
Presentation 2: AIRWAY Dr. Bushra Bilal Dr. Miada Mahmoud Rady CLS 243.
NICO ROGELIO.  A pathologic diagnosis defined as an abnormal, permanent enlargement of the airspaces distal to the terminal bronchiole accompanied by.
COPD ) ) Chronic Obstructive Pulmonary Disease. Introduction n COPD is a preventable and treatable disease with some significant extrapulmonary effects.
Disorders of the Respiratory System By : Amir Ashkan Ashrafian M.D.
Disorders of the respiratory system 2. Bronchitis is an obstructive respiratory disease that may occur in both acute and chronic forms. Acute bronchitis:
Management of Patients With Chronic Pulmonary Disease
Chronic obstructive pulmonary disease (COPD). Definition COPD (chronic obstructive pulmonary disease), is a progressive disease that makes it hard to.
Respiratory Emergencies.5 Dr. Maha Al Sedik 2015 Medical Emergency I.
Chronic Obstructive Pulmonary Disease 연세대학교 의과대학 응급의학교실 강사 조준호.
Copyright © 2013, 2010, 2006, 2002 by Saunders, an imprint of Elsevier Inc. Ignatavicius Chapter 32 Care of Patients with Noninfectious Lower Respiratory.
COPD Dr.S.Nandakumar. Professor of Medicine FOM, AIMST.
COPD Slides by Harleen Johal and Anna Longshaw Presented by Anna Longshow Notes available online.
Asthma and COPD Part 2.
Chronic Obstructive Pulmonary Disease Clinacal Pharmacy.
1 COPD (Definitions + Pathology) Dr.Mohsen SHAHEEN Pneumologist Dr.Mohsen SHAHEEN Pneumologist.
Common Respiratory Problems: COPD Asthma, emphysema bronchitis.
Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease(COPD)
Chronic Obstructive Pulmonary Disease
Diseases of the respiratory system lecture 3
COPD Dr MAMATHA SARTHI GPST3.
Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease that is characterized by persistent respiratory symptoms and.
Chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD)
Diseases of the Respiratory System
Chronic Obstructive Pulmonary Disease
Presentation transcript:

COPD Department of Internal Medicine Yonsei University College of Medicine Jae Ho Chung

Definition of COPD Chronic obstructive pulmonary disease (COPD) is a disease state characterized by airflow limitation that is not fully reversible. The airflow limitation is usually both progressive and associated with an abnormal inflammatory response of the lungs to noxious particles or gases. Chronic obstructive pulmonary disease (COPD) is a disease state characterized by airflow limitation that is not fully reversible. The airflow limitation is usually both progressive and associated with an abnormal inflammatory response of the lungs to noxious particles or gases.

n Diagnosis of COPD should be considered in cough, sputum production, or dyspnea, and/or exposure to risk factors for the disease n Dx is confirmatory by spirimetry n Post-bronchodilator FEV 1 <80 of predicted value and FEV 1 /FVC<70% n Diagnosis of COPD should be considered in cough, sputum production, or dyspnea, and/or exposure to risk factors for the disease n Dx is confirmatory by spirimetry n Post-bronchodilator FEV 1 <80 of predicted value and FEV 1 /FVC<70%

Definitions in COPD Condition Key features “Universe” of in Definition Definition Asthma ReversibilityPhysiology Chronic bronchitis Cough/sputumSymptoms Emphysema Alveolar destructionAnatomy

n Chronic bronchitis Clinical Dx Productive cough 3 months for 2 consecutive yrs n Emphysema Pathological Dx Permanent enlargement of the distal airspaces with destructions of their walls without fibrosis n Chronic bronchitis Clinical Dx Productive cough 3 months for 2 consecutive yrs n Emphysema Pathological Dx Permanent enlargement of the distal airspaces with destructions of their walls without fibrosis

Epidemiology

n COPD is the 4 th leading cause of death in the United States (behind heart disease, cancer, and cerebrovascular disease). n In 2000, the WHO estimated 2.74 million deaths worldwide from COPD. n In 1990, COPD was ranked 12 th as a burden of disease; by 2020 it is projected to rank 5 th. n COPD is the 4 th leading cause of death in the United States (behind heart disease, cancer, and cerebrovascular disease). n In 2000, the WHO estimated 2.74 million deaths worldwide from COPD. n In 1990, COPD was ranked 12 th as a burden of disease; by 2020 it is projected to rank 5 th.

Leading Causes of Deaths U.S All other causes of death 469, Chronic liver disease24, Nephritis26, Suicide29, Diabetes 64, Pneumonia and influenza93, Accidents94, Respiratory Diseases (COPD) 114, Cerebrovascular disease (stroke)158, Cancer 538, Cause of Death Number Heart Disease 724,269

Percent Change in Age-Adjusted Death Rates, U.S., Proportion of 1965 Rate –59% –64% –35% +163% –7% Coronary Heart Disease Coronary Heart Disease Stroke Other CVD COPD All Other Causes All Other Causes

n Between 1985 and 1995, the number of physician visits for COPD in the United States increased from 9.3 million to 16 million. n The number of hospitalizations for COPD in 1995 was estimated to be 500,000. Medical expenditures amounted to an estimated $14.7 billion. n Between 1985 and 1995, the number of physician visits for COPD in the United States increased from 9.3 million to 16 million. n The number of hospitalizations for COPD in 1995 was estimated to be 500,000. Medical expenditures amounted to an estimated $14.7 billion.

Physician Office Visits for Chronic and Unspecified Bronchitis, U.S. Source: National Ambulatory Medical Care Survey, NCHS 15 Number (Millions) Year

Pathophysiology

Risk Factors for COPD Host FactorsGenes (e.g. alpha1-antitrypsin deficiency) Hyperresponsiveness Lung growth ExposureTobacco smoke Occupational dusts and chemicals Infections Socioeconomic status Host FactorsGenes (e.g. alpha1-antitrypsin deficiency) Hyperresponsiveness Lung growth ExposureTobacco smoke Occupational dusts and chemicals Infections Socioeconomic status

Smoking n Dose-response relationship n 90% of all COPD are smoker (1) cilia movement ↓ (2) alveolar macrophage function↓ (3) lead to hyperthrophy and hyperplasia of mucus- secretory gland (4) inhibit antiprotease (5) cause PMN leukocytosis → release proteolytic enzyme  Only 15-20% of smokers manifest COPD FEV 1 n Dose-response relationship n 90% of all COPD are smoker (1) cilia movement ↓ (2) alveolar macrophage function↓ (3) lead to hyperthrophy and hyperplasia of mucus- secretory gland (4) inhibit antiprotease (5) cause PMN leukocytosis → release proteolytic enzyme  Only 15-20% of smokers manifest COPD FEV 1

COPD Risk and Smoking Cessation The best guide to the progression of COPD is the change in FEV 1 over time 1 1.British Thoracic Society. Guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997; 52(suppl 5).

Risk Factors n hereditary in 10% (alpha-1-antitrypsin) n environmental exposure (SO 2, NO 2 ) n socioeconomic factors (poverty) n hereditary in 10% (alpha-1-antitrypsin) n environmental exposure (SO 2, NO 2 ) n socioeconomic factors (poverty)

Pathogenesis of COPD NOXIOUS AGENT (tobacco smoke, pollutants, occupational agent) COPD Genetic factors Respiratory infection Other

Causes of Airflow Limitation n Reversible Ô Accumulation of inflammatory cells, mucus, and plasma exudate in bronchi Ô Smooth muscle contraction in peripheral and central airways Ô Dynamic hyperinflation during exercise n Reversible Ô Accumulation of inflammatory cells, mucus, and plasma exudate in bronchi Ô Smooth muscle contraction in peripheral and central airways Ô Dynamic hyperinflation during exercise

Causes of Airflow Limitation n Irreversible Ô Fibrosis and narrowing of the airways Ô Loss of elastic recoil due to alveolar destruction Ô Destruction of alveolar support that maintains patency of small airways n Irreversible Ô Fibrosis and narrowing of the airways Ô Loss of elastic recoil due to alveolar destruction Ô Destruction of alveolar support that maintains patency of small airways

Pathophysiology n 1. Airway limitation n 2. Hyperinflation n 3. Impaired gas exchange n 4. Pulmonary circulation n 5. Renal and Hormonal dysfunction n 6. Cachexia: TNF-alpha n 7. Peripheral muscle dysfunction n 8. Osteoporosis n 1. Airway limitation n 2. Hyperinflation n 3. Impaired gas exchange n 4. Pulmonary circulation n 5. Renal and Hormonal dysfunction n 6. Cachexia: TNF-alpha n 7. Peripheral muscle dysfunction n 8. Osteoporosis

Factors affecting dynamic compression n Reduced Lung recoil n e.g. low lung volumes or emphysema / loss of parenchyma n Airway structural stiffness. n  peripheral resistance Ô  pressure loss Ô EPP more peripheral location n  peripheral resistance Ô  pressure loss Ô EPP more peripheral location

Flow -Volume Curves in Health & Disease n Note changes in lung volume and  in flow in COPD and  relative flow in restrictive disease

Flow -Volume Curve:COPD

Natural History n FEV1 decline: 35ml/year after 25 yrs n COPD decline: 50~100ml/year n Exertional dyspnea: FEV1 <40% n Resting dyspnea: FEV1 <25% n Exacerbation: dyspnea, wheeze, cough, sputum (volume, viscosity, purulence), worsening hypoxemia n Usually infection n LV failure, arrhythmia, pneumothorax, pneumonia, pulmonary thromboembolism n FEV1 decline: 35ml/year after 25 yrs n COPD decline: 50~100ml/year n Exertional dyspnea: FEV1 <40% n Resting dyspnea: FEV1 <25% n Exacerbation: dyspnea, wheeze, cough, sputum (volume, viscosity, purulence), worsening hypoxemia n Usually infection n LV failure, arrhythmia, pneumothorax, pneumonia, pulmonary thromboembolism

Diagnosis

Symptom n Chronic cough : Present intermittently or every day Often present throughout the day; seldom only nocturnal n Chronic sputum production : Any pattern of chronic sputum production may indicate COPD n Chronic cough : Present intermittently or every day Often present throughout the day; seldom only nocturnal n Chronic sputum production : Any pattern of chronic sputum production may indicate COPD

n Dyspnea: Progressive (worsens over time) Persistent (present every day) Described by the patient as: "increased effort to breathe," "heaviness,""air hunger," or "gasping" Worse on exercise Worse on respiratory infection n Dyspnea: Progressive (worsens over time) Persistent (present every day) Described by the patient as: "increased effort to breathe," "heaviness,""air hunger," or "gasping" Worse on exercise Worse on respiratory infection

Bronchodilator reversibility test n Useful to help rule out asthma, pt`s prognosis, pt`s treatment decision n Who do not show FEV1 response may benefically symptomatically from longterm Tx n FEV1 or FVC 12% and 200ml n Useful to help rule out asthma, pt`s prognosis, pt`s treatment decision n Who do not show FEV1 response may benefically symptomatically from longterm Tx n FEV1 or FVC 12% and 200ml

ABG n Perform FEV1<40% or clinical sign of respiratory failure or right heart failure (central cyanosis, ankle swelling, jugular venous Pr increase) n Respiratory failure: PaO 2 <60mmHg with or without PaCO 2 <50mmHg n Perform FEV1<40% or clinical sign of respiratory failure or right heart failure (central cyanosis, ankle swelling, jugular venous Pr increase) n Respiratory failure: PaO 2 <60mmHg with or without PaCO 2 <50mmHg

n Symptoms free intervals in asthma n Long history of smoking in most patients with COPD n Progression of airflow obstruction in COPD n Aggravation of underlying symptoms in COPD n Right heart failure signs in COPD n Purulent sputum is a prominent feature in AECB n Symptoms free intervals in asthma n Long history of smoking in most patients with COPD n Progression of airflow obstruction in COPD n Aggravation of underlying symptoms in COPD n Right heart failure signs in COPD n Purulent sputum is a prominent feature in AECB Medical History in Asthma and COPD

Emphysema Bronchial asthma FEF 50 /FIF 50 = 0.16 FEF 50 /FIF 50 = 0.26 Difference in mechanisms of airway obstruction

CXR Spirometry Not compatible with COPD; make other diagnosis Compatible with COPD Clinical diagnosis / grading 1)Forced expiratory time 2)PEFR Not suggestiveSuggestive Review clinical diagnosis Suspected COPD Other diagnosis Management of COPD according to GOLD guideline Yes No

Early and prompt diagnosis of COPD Suspected walk-in patient a)Age > 40 years b)Smoking > 20 pack-years c)Progressive dyspnea d)Daily sputum production e)Cough/cold in winter Health care personnel pick up by screening questionnaire Physical Examination a)Barrel chest / prolonged expiration time b)Hyperresonance c)Subxyphoid apical pulse d)Wheezing with unforced expiration e)Diminished breath sounds CXR

Clinical Manifestation

Clinical Manifestations n All three disorders are present to some degree in clients with COPD n eventually chronic hypoxemia & hypercapnia result n All three disorders are present to some degree in clients with COPD n eventually chronic hypoxemia & hypercapnia result

Emphysema ( “ pink puffer ” ) n Characterized by enlargement of the air spaces distal to the terminal bronchioles and eventual destruction of alveolar walls where gas exchange takes place n due to loss of elastic recoil n Characterized by enlargement of the air spaces distal to the terminal bronchioles and eventual destruction of alveolar walls where gas exchange takes place n due to loss of elastic recoil

Chronic Bronchitis ( “ blue bloater ” ) n Characterized by excessive mucus production, reduced mucus clearance, and chronic cough (>3 months/year X two years) n associated with enlargement of bronchial mucous glands,  number of goblet cells, and impaired cilia function n Characterized by excessive mucus production, reduced mucus clearance, and chronic cough (>3 months/year X two years) n associated with enlargement of bronchial mucous glands,  number of goblet cells, and impaired cilia function

Responses to hypoxia n Emphysema: n proportionate loss of V & P (no V/Q mismatch) n struggle and often over ventilate in an attempt to maintain normal blood gas levels hence, known as “ pink puffers ” n Emphysema: n proportionate loss of V & P (no V/Q mismatch) n struggle and often over ventilate in an attempt to maintain normal blood gas levels hence, known as “ pink puffers ”

n Chronic bronchitis: n excessive bronchial secretions and a/w obstruction lead to V/Q mismatch (  V) n hypoxemia, cyanosis, and eventually cor pulmonale with peripheral edema) hence, known as “ blue bloaters ” n Chronic bronchitis: n excessive bronchial secretions and a/w obstruction lead to V/Q mismatch (  V) n hypoxemia, cyanosis, and eventually cor pulmonale with peripheral edema) hence, known as “ blue bloaters ”

AP diameter ↑ Hoover`s sign

Kussmaul`s sign: 흡기시에 neck vein 이 collapse 되지 않고 distention

Complications n respiratory infections n rupture of blebs leading to spontaneous pneumothorax n polycythemia vera n cor pulmonale n respiratory failure n respiratory infections n rupture of blebs leading to spontaneous pneumothorax n polycythemia vera n cor pulmonale n respiratory failure